major
asthmat
patient
respond
well
control
medic
inhal
corticosteroid
longact
bagonist
howev
subset
patient
respond
multipl
control
medic
includ
omalizumab
asthma
symptom
remain
poorli
control
group
patient
label
refractori
asthma
ra
sever
asthma
patient
experi
high
level
morbid
diseas
mani
patient
requir
chronic
system
steroid
therapi
result
sever
side
effect
add
morbid
heavi
use
health
care
servic
emerg
depart
hospit
patient
ra
account
disproportion
higher
health
care
cost
estim
patient
sever
ra
treatment
option
ra
limit
primarili
lack
understand
mechan
asthma
heterogen
diseas
base
clinic
laboratori
find
asthma
variabl
classifi
atop
versu
nonatop
asthma
eosinophil
versu
neutrophil
versu
noneosinophilicnonneutrophil
asthma
obesityassoci
asthma
asthmachron
obstruct
pulmonari
diseas
overlap
syndrom
h
asthma
h
h
asthma
h
asthma
exampl
sever
asthma
ra
occur
within
categori
patient
unclear
whether
singl
multipl
mechan
oper
patient
sever
ra
previou
studi
identifi
number
factor
patient
sever
asthma
heighten
activ
type
h
interferon
pathway
type
h
cell
type
cell
airway
neutrophilia
implic
patient
ra
level
type
cytokin
increas
asthmat
patient
howev
associ
level
h
cytokin
human
asthma
associ
neutrophil
asthma
unlik
report
mous
model
asthma
increas
epitheli
injuri
smooth
muscl
hyperplasia
hypertrophi
airway
remodel
recogn
intrins
factor
ra
extern
factor
associ
ra
includ
heighten
exposur
sensit
allergen
air
pollut
infect
heighten
level
select
cytokinesinflammatori
mediat
associ
mani
forego
subgroup
ra
despit
progress
field
need
examin
precis
molecular
mechan
heterogen
ra
allow
develop
target
therapeut
intervent
address
matter
studi
patient
ra
compar
patient
nonrefractori
asthma
nra
healthi
control
subject
bronchoalveolar
lavag
bal
fluid
serum
analyz
biomolecul
level
correl
clinic
laboratori
featur
asthma
latter
includ
pulmonari
function
pc
methacholin
allerg
sensit
fraction
exhal
nitric
oxid
feno
bodi
mass
index
blood
eosinophil
count
total
ige
level
bal
fluid
inflammatori
cell
count
eosinophil
neutrophil
lymphocyt
macrophag
count
indic
airway
tissu
inflamm
quantit
histolog
evalu
bronchial
tissu
basement
thick
result
microbiolog
studi
bal
tissu
biopsi
airway
brush
focu
articl
neutrophil
phenotyp
ra
studi
subject
ra
recruit
outpati
clinic
nation
jewish
health
patient
nra
healthi
control
subject
recruit
commun
studi
protocol
bronchoscopi
bal
approv
institut
review
board
hs
written
inform
consent
obtain
studi
subject
patient
allow
continu
routin
medic
asthmat
patient
comprehens
phenotyp
laboratori
workup
latter
includ
full
pulmonari
function
test
methacholin
test
fev
predict
valu
chest
comput
tomographi
ct
feno
valu
blood
test
result
eosinophil
total
ige
level
ige
antibodi
level
appropri
bronchoscopi
bal
airway
brush
endobronchi
biopsi
see
fig
articl
onlin
repositori
wwwjacionlineorg
forego
procedur
perform
describ
previous
bal
fluid
process
within
hour
cell
isol
mean
centrifug
supernat
fluid
aliquot
small
sampl
frozen
total
bal
fluid
cell
differenti
count
pcrbase
respiratori
viral
panel
differ
respiratori
virus
bal
cell
bronchial
brush
pcrbase
test
mycoplasma
pneumonia
chlamydophila
pneumonia
airway
biopsi
specimen
brush
bal
cell
bal
cultur
triplic
bacteria
mycobacterium
tuberculosi
nontubercul
mycobacteria
quantit
analysi
airway
tissu
inflammatori
cell
includ
mast
cell
use
immunohistochem
stain
perform
nation
jewish
health
clinic
laboratori
adxadvanc
diagnost
lab
nation
jewish
health
aliquot
bal
fluid
serum
analyz
total
biomolecul
human
discoveri
map
myriad
rbm
austin
tex
list
biomolecul
analyz
use
method
present
tabl
articl
onlin
repositori
wwwjacionlineorg
perform
pathway
analys
biomolecul
distinguish
ra
nra
use
multipl
softwar
enrichnetorg
web
site
gene
ontolog
go
biolog
process
molecular
function
reactom
kyoto
encyclopedia
gene
genom
comparison
studi
group
done
mannwhitney
u
test
comparison
among
multipl
studi
group
perform
kruskalw
test
follow
dunn
test
correct
multipl
comparison
addit
perform
benjaminihochberg
test
multipl
comparison
correct
fals
discoveri
fals
discoveri
rate
test
set
pearson
correl
coeffici
use
calcul
correl
coeffici
statist
analys
perform
prism
softwar
graphpad
softwar
la
jolla
calif
recruit
healthi
control
subject
patient
wellcontrol
asthma
patient
ra
defin
american
thorac
societi
definit
patient
nra
meet
criteria
ra
asthma
symptom
well
control
inhal
corticosteroid
control
thirtysix
percent
patient
ra
take
system
steroid
mgd
asthmat
patient
histori
current
past
smoke
exclud
studi
demograph
detail
studi
popul
shown
tabl
healthi
control
subject
patient
nra
younger
patient
ra
tabl
bodi
mass
index
significantli
differ
among
studi
group
patient
ra
atop
patient
nra
healthi
control
subject
judg
skin
test
posit
presenc
ige
antibodi
environment
allergen
pulmonari
function
indic
forc
vital
capac
fvc
fev
significantli
lower
revers
significantli
higher
patient
ra
compar
nra
differ
pc
methacholin
patient
ra
nra
feno
valu
differ
among
studi
group
blood
eosinophil
count
total
ige
level
increas
asthmat
patient
patient
ra
nra
differ
patient
ra
nra
neither
bal
fluid
airway
tissu
eosinophil
count
show
signific
differ
nra
ra
group
contrast
bal
fluid
airway
tissu
neutrophil
bal
lymphocyt
count
increas
patient
ra
surprisingli
number
tissu
cell
mostli
repres
mast
cell
decreas
patient
ra
subepitheli
basement
membran
thick
sign
airway
remodel
significantli
increas
asthmat
patient
greatest
thick
occur
patient
ra
biomolecul
assay
human
discoverymap
multiplex
assay
less
detect
limit
see
fig
b
one
hundr
one
biomolecul
show
signific
differ
among
studi
group
healthi
control
subject
patient
nra
patient
ra
fiftytwo
biomolecul
significantli
differ
either
multigroup
comparison
comparison
patient
ra
nra
tabl
ii
thirtyseven
biomolecul
distinguish
patient
ra
nra
tabl
ii
see
fig
c
bal
fluid
neutrophil
one
cell
type
distinguish
patient
ra
nra
focus
neutrophilassoci
biomolecul
studi
identifi
neutrophilassoci
biomolecul
level
significantli
increas
patient
ra
compar
patient
nra
healthi
control
subject
tabl
iii
biomolecul
show
signific
posit
correl
bal
fluid
neutrophil
count
tabl
iv
four
biomolecul
show
signific
correl
noteworthi
level
one
biomolecul
macrophag
inflammatori
protein
correl
bal
fluid
eosinophil
count
classifi
biomolecul
base
publish
cellular
sourc
see
tabl
articl
onlin
repositori
wwwjacionlineorg
classif
suggest
innat
immun
airway
tissu
cell
primari
sourc
raassoci
proneutrophil
biomolecul
also
impli
activ
innat
immun
airway
tissu
cell
contribut
significantli
ra
biomolecul
assay
undetect
one
hundr
seventytwo
biomolecul
show
differ
among
studi
group
fourteen
biomolecul
significantli
differ
among
studi
group
also
patient
nra
ra
tabl
v
biomolecul
also
detect
bal
fluid
differ
among
studi
group
includ
ficolin
matrix
metalloproteinas
mmp
thrombospondin
apolipoprotein
e
human
epididymi
protein
neuropilin
next
examin
correl
serum
biomolecul
bal
fluid
inflammatori
cell
see
tabl
articl
onlin
repositori
wwwjacionlineorg
five
biomolecul
correl
increas
bal
fluid
neutrophil
growth
note
infect
subclin
natur
patient
report
symptom
acut
infect
fever
coryza
pharyng
myalgia
patient
chest
ct
summari
chest
ct
find
patient
posit
result
infect
shown
tabl
articl
onlin
repositori
wwwjacionlin
org
one
patient
pseudomona
speci
consolid
patient
serratia
marcescen
infiltr
patient
groundglass
opac
rest
patient
sign
acut
infect
next
examin
effect
infect
cellular
molecular
paramet
patient
ra
anticip
infect
increas
frequenc
neutrophil
eosinophil
airway
compar
seen
patient
nra
see
fig
b
associ
dramat
increas
level
neutrophil
granular
protein
myeloperoxidas
see
fig
number
proneutrophil
biomolecul
especi
thrombospondin
serum
amyloid
saa
lipocalin
neutrophil
activ
conserv
cystein
contain
ccchemokin
see
fig
b
although
forego
chang
statist
signific
group
infectionposit
patient
ra
increas
bal
fluid
neutrophil
count
infectionposit
patient
ra
increas
neutrophil
frequenc
threshold
base
normal
rang
clinic
laboratori
bal
fluid
ten
infectionposit
neutrophil
asthmat
patient
increas
eosinophil
frequenc
bal
fluid
convers
infectionposit
nonneutrophil
patient
increas
eosinophil
count
bal
fluid
compar
bal
fluid
neutrophil
frequenc
percentag
absolut
neutrophil
count
blood
among
infectionposit
infectionneg
patient
ra
nra
total
patient
ra
infectionposit
ra
infectionneg
ra
receiv
system
steroid
could
direct
effect
blood
bal
fluid
neutrophil
count
reason
analyz
data
without
inclus
patient
receiv
oral
corticosteroid
ocss
bal
fluid
neutrophil
count
increas
infectionposit
infectionneg
patient
ra
regardless
oc
use
compar
healthi
control
subject
fig
blood
neutrophil
count
also
increas
infectionposit
infectionneg
patient
ra
data
analyz
entir
group
fig
b
howev
increas
lost
blood
bal
fluid
fig
c
infectionneg
ra
group
patient
receiv
ocss
exclud
analysi
result
suggest
blood
neutrophilia
infectionneg
patient
ra
caus
ocss
strikingli
absolut
neutrophil
number
remain
increas
infectionposit
ra
group
even
patient
receiv
ocss
exclud
analysi
result
indic
increas
absolut
neutrophil
count
could
serv
blood
biomark
airway
infect
patient
ra
result
also
suggest
blood
neutrophilia
subgroup
due
airway
infect
fig
c
asthma
type
immun
respons
diseas
eosinophil
play
import
role
note
earlier
median
bal
fluid
eosinophil
number
increas
significantli
patient
ra
compar
nra
infect
contribut
ra
signific
number
patient
reason
former
might
affect
eosinophil
influx
subclin
infect
plausibl
explan
increas
airway
neutrophil
count
infectionposit
patient
ra
caus
neutrophil
asthma
infectionneg
patient
ra
major
interest
us
goal
compar
serum
proneutrophil
biomolecul
level
infectionneg
infectionposit
patient
ra
fig
level
increas
serum
infectionneg
patient
ra
compar
infectionposit
patient
ra
nra
interestingli
bal
fluid
concentr
molecul
increas
infectionneg
patient
ra
compar
infectionposit
patient
ra
result
rais
possibl
system
inflammatori
process
contribut
airway
neutrophilia
infectionneg
patient
ra
next
compar
level
creactiv
protein
solubl
serum
stimul
also
known
suppressor
tumorigen
molecul
associ
atherosclerosi
cardiovascular
diseas
system
inflammatori
diseas
inde
level
molecul
increas
infectionneg
infectionposit
patient
neutrophil
asthma
fig
erythrocyt
sediment
rate
similar
group
concern
potenti
role
inhal
corticosteroid
airway
neutrophilia
goal
compar
inhal
corticosteroid
treatment
patient
nra
ra
see
tabl
articl
onlin
repositori
wwwjacionlineorg
patient
ra
receiv
highdos
inhal
steroid
longact
bagonist
contrast
patient
nra
receiv
lowto
mediumdos
inhal
steroid
thu
possibl
differ
dose
inhal
steroid
contribut
airway
neutrophilia
next
examin
clinic
correl
airway
inflammatori
cell
biomolecul
posit
correl
r
p
age
patient
bal
pmn
count
age
also
posit
correl
fvc
r
p
bal
fluid
level
r
p
level
proneutrophil
biomolecul
includ
r
r
bal
fluid
pmn
count
bal
fluid
eosinophil
lymphocyt
blood
eosinophil
count
neg
correl
fvc
percentag
see
tabl
articl
onlin
repositori
wwwjacionlineorg
cell
larg
exclus
repres
mast
cell
correl
level
bal
biomolecul
level
bal
fluid
biomolecul
correl
pulmonari
function
indic
myoglobin
level
neg
correl
fvc
percentag
wherea
prostasin
level
neg
correl
revers
posit
fev
percentag
perform
pathway
analys
bal
fluid
biomolecul
distinguish
patient
ra
nra
compar
pathway
result
use
go
biolog
process
molecular
function
reactom
kyoto
encyclopedia
gene
genom
data
shown
go
analysi
identifi
meaning
pathway
top
pathway
includ
neutrophil
chemotaxi
chemokin
receptor
signal
fibroblast
growth
factor
stimul
cellular
respons
see
tabl
articl
onlin
repositori
wwwjacionlineorg
show
ra
associ
increas
neutrophil
lymphocyt
count
airway
mention
previous
specif
focus
neutrophil
asthma
articl
concurr
increas
level
multitud
biomolecul
known
associ
innat
immun
airway
tissu
respons
identifi
biomolecul
increas
level
asthmat
patient
distinguish
ra
nra
sixteen
biomolecul
correl
neutrophil
asthma
vast
major
biomolecul
known
produc
macrophag
airway
epitheli
cell
indirectli
point
role
patient
neutrophil
asthma
pathway
analysi
identifi
neutrophil
influx
import
biolog
process
ra
multipl
previou
studi
demonstr
similar
role
neutrophil
inflamm
sever
asthma
ra
group
resembl
cluster
neutrophil
sarp
cohort
subsequ
studi
sarp
patient
increas
neutrophil
mix
neutrophil
eosinophil
count
sputum
cluster
c
associ
asthma
sever
patient
ra
similar
cluster
h
mix
neutrophiliceosinophil
multin
studi
hink
et
al
cluster
sever
asthma
associ
increas
level
sputum
one
weak
studi
patient
ra
significantli
older
patient
nra
ra
preval
older
patient
led
unintend
recruit
outcom
increas
age
associ
sputum
neutrophilia
even
nonasthmat
subject
thu
increas
age
could
affect
qualiti
quantiti
mediat
involv
neutrophil
asthma
use
commerci
avail
multiplex
assay
servic
measur
biomolecul
multiplex
assay
less
sensit
highli
sensit
assay
eg
elisa
perhap
explain
detect
typic
type
eg
type
cytokin
howev
scope
biomolecul
detect
use
assay
advantag
one
outstand
issu
relat
heighten
product
proneutrophil
biomolecul
induc
product
patient
ra
observ
subclin
infect
bacteri
viral
one
third
patient
ra
subclin
infect
could
stimul
product
proneutrophil
biomolecul
use
standard
microbiolog
cultur
detect
bacteria
sensit
cultur
rel
low
compar
dnabas
technolog
possibl
new
technolog
identifi
addit
patient
subclin
infect
could
explain
increas
airway
neutrophil
count
current
classifi
infectionneg
patient
persist
infect
subclin
level
subgroup
patient
rais
concern
defect
immun
respons
inabl
clear
infect
could
primari
secondari
ongo
treatment
steroid
inhal
steroid
patient
system
steroid
patient
ra
potenti
role
inhal
steroid
patient
subclin
infect
address
time
discontinu
patient
ra
consid
uneth
detect
decreas
level
patient
ra
low
level
previous
report
sputum
asthmat
patient
patient
rhinoviru
infect
import
defens
infect
decreas
could
impair
clearanc
infect
macrophag
scaveng
infect
dead
cell
import
resolut
inflamm
axl
receptor
tyrosin
kinas
specif
express
airway
macrophag
observ
decreas
express
axl
receptor
bal
suggest
decreas
express
macrophag
consequ
impair
scaveng
function
latter
could
promot
persist
infect
thrombospondin
multifunct
pleiotrop
protein
level
increas
patient
ra
recent
report
inhibit
bactericid
activ
neutrophil
delay
clearanc
lung
infect
thu
identifi
number
biomolecul
could
promot
persist
subclin
infect
patient
ra
system
glucocorticoid
known
induc
blood
tissu
neutrophilia
thirtysix
percent
patient
ra
take
system
steroid
analysi
patient
take
ocss
suggest
system
steroid
contribut
blood
airway
neutrophilia
infectionneg
patient
ra
understand
role
inhal
steroid
patient
airway
neutrophilia
incomplet
previou
studi
show
system
inhal
steroid
associ
tissu
neutrophilia
howev
studi
done
small
number
patient
result
show
trend
increas
airway
neutrophil
count
inhal
steroid
patient
nra
ra
receiv
inhal
steroid
studi
howev
unlik
patient
ra
patient
nra
receiv
maxim
dose
inhal
steroid
thu
possibl
higher
dose
inhal
steroid
patient
ra
contribut
extent
airway
neutrophilia
environment
toxic
frequent
induc
cytokineschemokin
elicit
lowlevel
neutrophil
inflamm
could
cumul
effect
age
h
immun
respons
induc
neutrophil
inflamm
anim
model
assay
detect
like
low
sensit
assay
howev
assay
detect
increas
level
multipl
proneutrophil
biomolecul
includ
saa
thrombospondin
epiderm
growth
factor
receptor
advanc
glycosyl
end
product
except
last
significantli
correl
bal
fluid
neutrophil
count
saa
induc
granulocyt
colonystimul
factor
stimul
neutrophil
gener
also
induc
h
induc
h
marker
system
inflamm
directli
induc
neutrophil
inflamm
also
induc
cytokineschemokin
could
indirectli
affect
neutrophil
inflamm
find
biomolecul
agreement
mani
previou
studi
similar
find
discrimin
sever
moder
asthma
sarp
studi
level
previous
report
increas
sputum
bal
fluid
patient
ra
neutrophil
asthma
although
exist
neutrophil
asthma
absenc
infect
known
mani
year
mechan
poorli
understood
studi
identifi
uniqu
subgroup
infectionneg
patient
neutrophil
ra
select
associ
increas
marker
inflamm
serum
marker
includ
concomit
increas
creactiv
protein
level
patient
suggest
system
inflammatori
process
akin
observ
patient
atherosclerot
cardiovascular
autoinflammatori
diseas
remark
subgroup
patient
also
increas
addit
cardiovascular
risk
factor
solubl
receptor
recogn
latter
nonspecif
biomark
system
inflamm
four
infectionneg
patient
neutrophil
ra
infectionposit
patient
neutrophil
ra
histori
cardiovascular
diseas
therefor
frequenc
exist
cardiovascular
diseas
explain
system
serum
increas
level
inflammatori
cytokin
also
find
correl
inflammatori
cytokin
common
comorbid
diabet
autoimmun
disord
multipl
known
mechan
induct
constel
inflammatori
cytokin
also
constitut
senescenceassoci
secretori
product
senesc
biolog
process
defend
dna
damageinduc
carcinogenesi
produc
multipl
cytokin
contribut
system
inflamm
recent
shown
induc
cellular
senesc
correl
neutrophil
asthma
age
also
rais
possibl
senesc
contribut
increas
proneutrophil
cytokin
profil
serum
addit
studi
need
establish
relationship
cellular
senesc
predisposit
neutrophil
ra
note
infectionposit
patient
ra
neutrophilia
bal
fluid
underscor
notion
subclin
infect
nearli
half
increas
eosinophil
count
bal
fluid
suggest
type
immunodomin
asthma
type
cytokin
inhibit
proneutrophil
cytokin
could
explain
lack
neutrophilia
howev
absenc
neutrophilia
noneosinophil
infectionposit
patient
ra
suggest
defect
immun
respons
perhap
activ
immun
evas
microbi
organ
serum
biomolecul
differ
among
studi
group
biomolecul
overlap
bal
fluid
howev
pattern
chang
differ
bal
fluid
four
biomolecul
show
reduc
express
patient
nra
ra
compar
express
healthi
control
subject
reason
reduc
express
patient
nra
ra
clear
ficolin
biomolecul
serum
distinguish
ra
nra
ficolin
recognit
molecul
lectin
pathway
complement
system
defici
associ
increas
infect
subclin
infect
one
mechan
ra
subgroup
patient
import
test
target
bacteri
strainspecif
antibiot
therapi
awar
antibiot
therapi
patient
ra
produc
mix
result
past
failur
antibiot
therapi
studi
could
due
inappropri
select
studi
patient
eg
inclus
patient
infect
use
inappropri
antibiot
note
detect
gramposit
gramneg
bacteria
well
virus
patient
ra
result
underscor
import
select
appropri
antibiot
target
gramposit
vs
gramneg
bacteria
applic
properli
identifi
target
patient
popul
lowlevel
system
inflamm
inde
caus
airway
neutrophilia
infectionneg
patient
ra
hypothesi
test
use
therapeut
agent
target
molecul
therapeut
agent
alreadi
use
patient
rheumatolog
condit
number
cell
repres
mostli
mast
cell
reduc
patient
ra
reduc
number
tryptaseposit
cell
repres
mast
cell
patient
sever
asthma
previous
report
sarp
studi
thought
due
loss
tryptas
consequ
mast
cell
degranul
howev
unlik
tryptas
cellsurfac
marker
granular
protein
expect
affect
mast
cell
degranul
possibl
reduc
cell
number
consequ
underli
diseas
process
acknowledg
excel
technic
assist
christena
kolakowski
allen
steven
clinic
implic
studi
identifi
airway
neutrophil
proneutrophil
biomolecul
signific
contributor
ra
subgroup
neutrophil
asthma
associ
subclin
infect
group
like
benefit
specif
antimicrobi
therapi
neutrophil
asthma
without
subclin
infect
show
sign
system
inflamm
therapi
target
proneutrophil
biomolecul
autoinflamm
like
control
asthma
subgroup
least
detect
dose
ldd
determin
mean
sd
blank
read
result
less
ldd
variabl
result
greater
ldd
lower
limit
quantit
lloq
lowest
concentr
analyt
sampl
reliabl
detect
total
error
meet
laboratori
requir
accuraci
myriad
rbm
requir
accuraci
concentr
analyt
coeffici
variat
replic
standard
sampl
mip
macrophag
inflammatori
protein
nd
detect
bronchiol
consist
aspir
ground
glass
consist
asthma
consist
reflux
esophag
thicken
bronchial
wall
thicken
consist
asthma
bronchiectasi
infiltr
hiatal
hernia
esophag
thicken
consist
reflux
air
trap
bronchial
wall
thicken
consist
aspir
consist
asthma
tracheobronchomalacia
pulmonari
hypertens
consist
reflux
esophag
thicken
hiatal
hernia
bronchial
wall
thicken
consist
aspir
consist
asthma
dysmotil
consist
reflux
tracheobronchomalacia
bronchial
wall
thicken
consist
asthma
consist
aspir
dysmotil
consist
reflux
bronchial
wall
thicken
bronchiectasi
air
trap
hiatal
hernia
dysmotil
hiatal
hernia
esophag
thicken
bronchial
wall
thicken
air
trap
consist
reflux
bronchiectasi
bronchial
wall
thicken
consist
asthma
scar
hiatal
hernia
dysmotil
bronchial
wall
thicken
ground
glass
esophag
thicken
hiatal
hernia
dysmotil
consist
reflux
bronchial
wall
thicken
consist
asthma
consist
aspir
hiatal
hernia
consist
reflux
esophag
thicken
bronchial
wall
thicken
hiatal
hernia
esophag
thicken
hiatal
hernia
bronchiectasi
consist
aspir
bronchial
wall
thicken
air
trap
bronchial
wall
thicken
consist
asthma
esophag
thicken
dysmotil
consist
reflux
air
trap
tracheobronchomalacia
air
trap
bronchial
wall
thicken
consolid
hiatal
hernia
esophag
thicken
bronchiectasi
consist
reflux
tracheobronchomalacia
consist
reflux
consist
aspir
consist
asthma
bronchial
wall
thicken
air
trap
esophag
thicken
bronchial
wall
thicken
atelectasi
hiatal
hernia
bronchial
wall
thicken
scar
granuloma
air
trap
tracheobronchomalacia
bronchial
wall
thicken
atelectasi
air
trap
consist
asthma
bronchial
wall
thicken
scar
ground
glass
consist
reflux
hiatal
hernia
consist
asthma
consist
aspir
bronchial
wall
thicken
atelectasi
scar
air
trap
consist
asthma
esophag
thicken
bronchial
wall
thicken
atelectasi
scar
air
trap
consist
reflux
dysmotil
consist
aspir
esophag
thicken
bronchial
wall
thicken
air
trap
consist
asthma
bronchial
wall
thicken
atelectasi
scar
air
trap
tracheobronchomalacia
dysmotil
